Dinckan Ayhan, Aliosmanoglu Ibrahim, Kocak Huseyin, Sari Ramazan, Erdogan Okan, Ertug Zeki, Suleymanlar Gultekin, Gurkan Alihan
Akdeniz University, Organ Transplantation Institute, Antalya, Turkey.
Ann Transplant. 2012 Jul-Sep;17(3):14-9. doi: 10.12659/aot.883453.
Pancreas transplantation methods, such as simultaneous pancreas-kidney (SPK) transplantation and pancreas-after-kidney (PAK) transplantation, have become the most important treatments for patients with type-1 diabetes mellitus (DM)-related end-stage renal diseases (ESRD). The purpose of the study was to compare the clinical results of the pancreas graft in patients after SPK and PAK transplantations and to present the findings of our 5-year follow-up.
MATERIAL/METHOD: A total of 55 patients who had kidney and pancreas transplantation between February 2003 and December 2010 were included in the study. The patients were divided into 2 groups based on the timing of the pancreas transplantation: SPK (n=21) and PAK (n=34).
The patients in the SPK group consisted of 13 males and 8 females, with a mean age of 33.6±6.8 years; whereas 25 males and 9 females formed the PAK group, with a mean age of 32.0±6.0 years. In the early postoperative period, the SPK group had 3 patients with vascular thrombosis (2 venous, 1 arterial) and the PAK group had 7 patients with thrombosis (4 venous, 3 arterial) (p=0.319). At the end of the 5-year follow-up, the patient, kidney and pancreas survival rates in the SPK group were 95.2%, 95.2%, and 61.9% respectively, and the corresponding values in the PAK group were 97%, 91.2%, 61.8% (p=0.382, p=0.504, p=0.927).
We concluded that PAK is just as effective as SPK to prevent the destructive effects of DM when the waiting time for SPK is long and a potential live donor is present.
胰腺移植方法,如胰肾联合移植(SPK)和肾后胰腺移植(PAK),已成为1型糖尿病(DM)相关终末期肾病(ESRD)患者最重要的治疗方法。本研究的目的是比较SPK和PAK移植术后患者胰腺移植物的临床结果,并展示我们5年随访的结果。
材料/方法:共有55例在2003年2月至2010年12月期间接受肾和胰腺移植的患者纳入本研究。根据胰腺移植的时间将患者分为2组:SPK组(n = 21)和PAK组(n = 34)。
SPK组患者包括13名男性和8名女性,平均年龄为33.6±6.8岁;而PAK组由25名男性和9名女性组成,平均年龄为32.0±6.0岁。术后早期,SPK组有3例患者发生血管血栓形成(2例静脉血栓,1例动脉血栓),PAK组有7例患者发生血栓形成(4例静脉血栓,3例动脉血栓)(p = 0.319)。在5年随访结束时,SPK组患者、肾脏和胰腺的生存率分别为95.2%、95.2%和61.9%,PAK组的相应值分别为97%、91.2%、61.8%(p = 0.382,p = 0.504,p = 0.927)。
我们得出结论,当SPK的等待时间较长且有潜在的活体供体时,PAK在预防DM的破坏作用方面与SPK同样有效。